Evidence map›Paper›PMID 24768611›Full record

ArticleHeart rhythm2014

Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice.

Efrat Kurtzwald-Josefson, Edith Hochhauser, Katia Bogachenko, Shiraz Harun-Khun, Guy Katz, Dan Aravot, Jonathan G Seidman, Christine E Seidman, Michael Eldar, Asher Shainberg and 1 more

Open access · greenAbstract read
In one paragraph

Article in Heart rhythm, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Atropine-induced sinus tachycardia protects against exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2020
    Trial
  2. Article
  3. Review
  4. HBK-10, A Compound with αPharmaceuticals (Basel, Switzerland) · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. SK4 KEMBO molecular medicine · 2017
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Efrat Kurtzwald-JosefsonLeviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Cardiac Research Lab, Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Edith HochhauserCardiac Research Lab, Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Katia BogachenkoFaculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel.
Shiraz Harun-KhunLeviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Guy KatzPinchas Borenstein Talpiot Medical Leadership Program, Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Leviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Dan AravotCardiac Research Lab, Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Jonathan G SeidmanDepartment of Genetics, Harvard Medical School, Boston, Massachusetts.
Christine E SeidmanDepartment of Genetics, Harvard Medical School, Boston, Massachusetts.
Michael EldarLeviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Asher ShainbergFaculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel.
Michael AradLeviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: michael.arad@sheba.health.gov.il.
Tel Aviv University · ILBar-Ilan University · ILHarvard University · USSheba Medical Center · IL

Funding

Molecular Signaling in Hypertrophic CardiomyopathyR01HL084553 · NHLBI · HARVARD MEDICAL SCHOOL · PI SEIDMAN, JONATHAN G · 2007 to 2022
$5.9M
NHLBI NIH HHS R01 HL084553
6 · The paper itself

Abstract

backgroundSpontaneous calcium release evoking delayed afterdepolarization is believed to cause catecholaminergic polymorphic ventricular tachycardia (CPVT), a lethal human arrhythmia provoked by exercise or emotional stress. β-Adrenergic blockers are the drug of choice, but fail to achieve complete arrhythmia control in some patients. These individuals often require flecainide, device implantation, and/or sympathetic denervation.

objectiveTo optimize the arrhythmia therapy by pharmacological inhibition of the sympathetic nervous system in the homozygous calsequestrin knockout (CASQ2(Δ/Δ)) mouse model of CPVT2.

methodsA heart telemetry device was implanted for continuous electrocardiographic recording at rest and during provocation testing. Calcium transients and abnormal calcium release were studied in cardiomyocytes isolated from adult mice. Adrenergic receptor expression was determined by using Western blotting and confocal microscopy.

resultsAdult CASQ2(Δ/Δ) mice suffer from complex ventricular arrhythmia at rest and ventricular tachycardia during treadmill exercise and after epinephrine injection. β-Adrenergic blockers, propranolol and metoprolol, attenuated arrhythmia at rest but not after stress. Reserpine had no efficacy in controlling arrhythmia. Agents with α-blocking activity, phentolamine or labetalol, abolished both exercise- and epinephrine-induced arrhythmia. In contrast, injection of α-adrenergic agonist phenylephrine reproducibly provoked ventricular tachycardia. Isolated cardiomyocytes from CASQ2(Δ/Δ) mice had delayed calcium release waves upon exposure to sympathetic agonists, which were abolished by phentolamine. Hearts of calsequestrin-mutant mice expressed more α1-adrenergic receptor than did wild type control mice (P < .05).

conclusionWe identified a contribution of the α-adrenergic pathway to the pathogenesis of catecholamine-induced arrhythmia. α-Blockade emerges as an effective therapy in the murine model of CPVT2 and should be tried in humans resistant to β-blockers.

Indexed as

Adrenergic alpha-AntagonistsAnimalsBlotting, WesternCalsequestrinDisease Models, AnimalElectrocardiographyGene Expression RegulationMiceMice, Inbred C57BLMice, KnockoutMicroscopy, ConfocalMyocytes, CardiacPolymorphic Catecholaminergic Ventricular TachycardiaReceptors, Adrenergic, alphaTachycardia, VentricularAdrenergic alpha-AntagonistsCalsequestrinReceptors, Adrenergic, alphaArrhythmiaCalciumCalsequestrinCPVTMouse modelSympatheticα-Adrenergic receptor

Identifiers

PMID24768611
PMCPMC4108570
OpenAlexW2090058377

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.